2025 · 2nd Quarter (Apr 1 - June 30)

NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Filed by NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD).

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: Not reported
Expenses: $50,000.00
Registrant: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)
Filing UUID: 29ab9ef1-02ef-4e3a-8117-a07e4250dc50
Termination date: Not reported

Expense method: B

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Priority Review Voucher Reauthorization. Newborn Screening.

MMM · Medicare/Medicaid

Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.

PHA · Pharmacy

Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. H.R.1414: Camerons Law. Promising Pathways Act 2.0.

Literal federal measure citations: H.R.1414

BUD · Budget/Appropriations

Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Advanced Research Projects Agency - Health (ARPA-H) Appropriations. NIH / FDA Appropriations. HHS RIFs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.